Biotech up­start rides the up­surge in ra­dio­phar­ma R&D to $88M round with mar­quee in­vestors

Bel­gian biotech up­start Pre­cir­ix had raised $40 mil­lion in a Se­ries A from 6 VC back­ers four years ago. Now, all of those in­vestors have come back, join­ing a few new big­wig VCs in the com­pa­ny’s next raise — and its largest so far.

The out­fit, start­ed in 2014 by a group of sci­en­tists out of the Uni­ver­si­ty of Brus­sels, raised $88 mil­lion in a Se­ries B, which will last the com­pa­ny some­where be­tween 2-3 years. New in­vestors INKEF Cap­i­tal, Jeito Cap­i­tal and For­bion joined up as co-lead in­vestors along­side all the VC back­ers from Pre­cir­ix’s A round: Gimv, Health­Cap, No­vo Hold­ings, Pon­tif­ax Ven­ture Cap­i­tal, V-Bio Ven­tures, and Bio­Med Part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER